KUALA LUMPUR (April 26): Property developer Yong Tai Bhd said its healthcare subsidiary has obtained approval from the Ministry of Health s Medical Review & Ethics Committee (MREC) for its Phase III clinical trial study of inactivated Covid-19 trial vaccines in Malaysia. The board wishes to announce that MREC had vide its letter dated April 23, approved the said Phase III Clinical Trial study to be carried out in Malaysia involving 3,000 subjects, the group said in a bourse filing today.
The health ministry has not made a statement on this matter so far.
Yong Tai said its unit, YTB Healthcare Sdn Bhds (YTBH), has formalised the Phase III clinical trial with its partner, Shenzhen Kangtai Biological Products Co Ltd (SZKT), since December last year. SZKT is a vaccine manufacturer in China.